PNC Financial Services Group Inc. lowered its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,225,034 shares of the medical research company’s stock after selling 323 shares during the period. PNC Financial Services Group Inc. owned about 0.58% of Edwards Lifesciences Corporation worth $144,846,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. UBS Asset Management Americas Inc. raised its position in shares of Edwards Lifesciences Corporation by 7.8% in the first quarter. UBS Asset Management Americas Inc. now owns 574,126 shares of the medical research company’s stock valued at $54,008,000 after buying an additional 41,636 shares during the last quarter. NF Trinity Capital Hong Kong Ltd acquired a new position in shares of Edwards Lifesciences Corporation in the first quarter valued at approximately $5,276,000. Karp Capital Management Corp acquired a new position in shares of Edwards Lifesciences Corporation in the first quarter valued at approximately $6,264,000. Sei Investments Co. raised its position in shares of Edwards Lifesciences Corporation by 14.3% in the first quarter. Sei Investments Co. now owns 221,249 shares of the medical research company’s stock valued at $20,813,000 after buying an additional 27,654 shares during the last quarter. Finally, Endurance Wealth Management Inc. raised its position in shares of Edwards Lifesciences Corporation by 3.1% in the first quarter. Endurance Wealth Management Inc. now owns 98,888 shares of the medical research company’s stock valued at $9,302,000 after buying an additional 2,975 shares during the last quarter. Institutional investors own 82.36% of the company’s stock.

A number of equities analysts have recently weighed in on the stock. Royal Bank Of Canada reissued a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st. BMO Capital Markets reissued a “buy” rating and issued a $132.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st. William Blair reissued an “outperform” rating on shares of Edwards Lifesciences Corporation in a research report on Monday, August 28th. BidaskClub lowered shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $155.00 price objective (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Edwards Lifesciences Corporation presently has an average rating of “Buy” and a consensus price target of $120.75.

In related news, VP Catherine M. Szyman sold 4,681 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $114.80, for a total transaction of $3,776,920.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 163,541 shares of company stock worth $18,712,719. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation (NYSE EW) traded up 1.79% during midday trading on Friday, reaching $113.50. 1,944,139 shares of the company’s stock traded hands. The company’s 50-day moving average price is $113.99 and its 200 day moving average price is $108.88. The stock has a market capitalization of $23.97 billion, a price-to-earnings ratio of 34.43 and a beta of 0.64. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.20. The firm had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.76 earnings per share. On average, equities research analysts expect that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “PNC Financial Services Group Inc. Cuts Holdings in Edwards Lifesciences Corporation (EW)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/16/pnc-financial-services-group-inc-cuts-holdings-in-edwards-lifesciences-corporation-ew.html.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.